MAPLIGHT THERAPEUTICS ($MPLT) posted quarterly earnings results for Q3 2026 on Monday, November 16th. The company reported earnings of -$0.97 per share, beating estimates of -$1.20 by $0.23. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market open this morning: -4.59%
You can see Quiver Quantitative's $MPLT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MAPLIGHT THERAPEUTICS Insider Trading Activity
MAPLIGHT THERAPEUTICS insiders have traded $MPLT stock on the open market 55 times in the past 6 months. Of those trades, 1 have been purchases and 54 have been sales.
Here’s a breakdown of recent trading of $MPLT stock by insiders over the last 6 months:
- CHRISTOPHER A. KROEGER (Chief Executive Officer) has made 0 purchases and 10 sales selling 339,565 shares for an estimated $9,254,144.
- ERIN PENNOCK FOFF (Chief Medical Officer) has made 0 purchases and 10 sales selling 62,513 shares for an estimated $1,858,558.
- JONATHAN GILLIS (CAO and Interim CFO) has made 0 purchases and 8 sales selling 47,146 shares for an estimated $1,454,817.
- ANATOL KREITZER (Chief Discovery Officer) has made 0 purchases and 8 sales selling 48,532 shares for an estimated $1,441,917.
- JAMES WOODRUFF LILLIE (Chief Scientific Officer) has made 0 purchases and 9 sales selling 51,862 shares for an estimated $1,043,569.
- KRISTOPHER HANSON (General Counsel) has made 0 purchases and 9 sales selling 42,037 shares for an estimated $873,411.
- TROY COX purchased 15,620 shares for an estimated $148,702
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
MAPLIGHT THERAPEUTICS Hedge Fund Activity
We have seen 56 institutional investors add shares of MAPLIGHT THERAPEUTICS stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NAN FUNG GROUP HOLDINGS LTD added 1,329,075 shares (+136.8%) to their portfolio in Q3 2026, for an estimated $13,543,274
- DEEP TRACK CAPITAL, LP added 1,318,101 shares (+inf%) to their portfolio in Q3 2026, for an estimated $13,431,449
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,310,227 shares (+1162.5%) to their portfolio in Q2 2026, for an estimated $46,958,535
- FCPM III SERVICES B.V. added 1,201,928 shares (+37.3%) to their portfolio in Q3 2026, for an estimated $12,247,646
- FMR LLC added 718,384 shares (+87.2%) to their portfolio in Q3 2026, for an estimated $7,320,332
- ADAR1 CAPITAL MANAGEMENT, LLC added 698,668 shares (+2636.8%) to their portfolio in Q3 2026, for an estimated $7,119,426
- BLACKROCK, INC. added 687,595 shares (+67.1%) to their portfolio in Q3 2026, for an estimated $7,006,593
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
MAPLIGHT THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $MPLT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 08/31/2026
- Canaccord Genuity issued a "Buy" rating on 07/28/2026
- HC Wainwright & Co. issued a "Buy" rating on 07/28/2026
- BMO Capital issued a "Outperform" rating on 07/21/2026
To track analyst ratings and price targets for MAPLIGHT THERAPEUTICS, check out Quiver Quantitative's $MPLT forecast page.
MAPLIGHT THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $MPLT recently. We have seen 9 analysts offer price targets for $MPLT in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $43.0 on 08/31/2026
- Ashwani Verma from UBS set a target price of $13.0 on 08/10/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $24.0 on 07/28/2026
- Sean Laaman from Morgan Stanley set a target price of $21.0 on 07/28/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $26.0 on 07/28/2026
- Malcolm Hoffman from BMO Capital set a target price of $46.0 on 07/21/2026
- Tiago Fauth from Raymond James set a target price of $46.0 on 06/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.